{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:38:03Z","timestamp":1789699083470,"version":"4.0.1"},"reference-count":34,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Precision oncology (PO) improves and extends the lives of patients living with cancer, but multiple studies have documented its underuse in practice. Specifically, studies note a significant lack of PO use within the Veterans Affairs (VA) medical system. A paucity of implementation of PO in oncologic practice poses a significant barrier to providing the most up-to-date guideline-based care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n While several studies have explored determinants of PO use, we sought to contribute to the body of knowledge by additionally focusing on the unique perspectives of patients, as well as conducting a comprehensive study within the VA medical system, the United States\u2019 largest single-payer health care system. We conducted interviews with both patients and providers at multiple VA sites to identify and characterize barriers and facilitators of PO use in clinical care.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using a qualitative descriptive approach, we conducted semistructured interviews with 17 patients with cancer and 16 oncology providers recruited from multiple VA sites. Cancer types included prostate, gastrointestinal, and lung. Data were analyzed via a team-based coding approach using directed content analysis. Data were coded and then aggregated into themes and mapped to the Theoretical Domains Framework (TDF) and Behavior Change Wheel sources of behavior (Capability, Opportunity, and Motivation) based on the consensus of the study team.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The patient sample consisted of 17 all-male veterans seen at VA oncology clinics in 2022. Participants predominantly self-identified as White (n=9, 52.9%) or Black (n=6, 35.3%), and the majority (n=11, 64.7%) held a high school degree or a higher level of education. The provider sample consisted of 16 physicians, all of whom held MD degrees and practiced oncology. The provider sample represented 6 states, was 50% (8\/16) female, and participants averaged 14 years in their current position. The overarching theme was the \u201cPrecision Oncology Feedback Loop,\u201d which captured the essence of the complex processes involved in facilitating PO care in the VA system. The TDF and Behavior Change Wheel helped categorize findings to identify where issues in the feedback loop could facilitate or generate barriers to care.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our findings expand on the current literature by highlighting both patient and provider experiences across key TDF domains (Environmental Context and Resources, Knowledge, Memory, and Attention). The conceptual model produced by the analysis illustrates the complexities associated with the implementation. Our findings support the design of multilevel interventions that target increased knowledge or education, improved workflow, and ease of communication to enhance PO delivery.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/84858","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:15:09Z","timestamp":1773069309000},"page":"e84858-e84858","source":"Crossref","is-referenced-by-count":1,"title":["Patient and Provider Experiences With Precision Oncology: Qualitative Descriptive Study at the Department of Veterans Affairs"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7230-8432","authenticated-orcid":false,"given":"Daniel","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-057X","authenticated-orcid":false,"given":"Kenneth","family":"Csehak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3262-2248","authenticated-orcid":false,"given":"Alexander","family":"Barbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-9712","authenticated-orcid":false,"given":"Christian","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1095-0364","authenticated-orcid":false,"given":"Antoinette","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-1239","authenticated-orcid":false,"given":"Stefanie","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-9272","authenticated-orcid":false,"given":"Danil","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1752-7303","authenticated-orcid":false,"given":"Scott","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-2122","authenticated-orcid":false,"given":"Allison","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"19","key":"R1","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","journal-title":"JAMA"},{"key":"R2","unstructured":"NCCN guidelines. National Comprehensive Cancer Network. 2025. URL: https:\/\/www.nccn.org\/guidelines\/category_1 [Accessed 25-03-2026]"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00359","article-title":"Uptake of KRAS testing and anti-EGFR antibody use for colorectal cancer in the VA","volume":"5","author":"Becker","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"R4","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.6004\/jnccn.2017.7011","article-title":"testing, tumor location, and survival in patients with stage IV colorectal cancer: SEER 2010-2013","volume":"15","author":"Charlton","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"R5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/COC.0000000000000875","article-title":"Socioeconomic determinants of the use of molecular testing in stage IV colorectal cancer","volume":"44","author":"Punekar","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"R6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1200\/OP.20.00174","article-title":"Closing the rural cancer care gap: three institutional approaches","volume":"16","author":"Levit","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"R7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/pros.24172","article-title":"Barriers and facilitators of germline genetic evaluation for prostate cancer","volume":"81","author":"Loeb","journal-title":"Prostate"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2021.04.025","article-title":"Precision medicine testing in ovarian cancer: the growing inequity between patients with commercial vs Medicaid insurance","volume":"162","author":"Gamble","journal-title":"Gynecol Oncol"},{"issue":"11","key":"R9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33205","article-title":"Racial and ethnic disparities among participants in precision oncology clinical studies","volume":"4","author":"Aldrighetti","journal-title":"JAMA Netw Open"},{"issue":"7","key":"R10","doi-asserted-by":"publisher","first-page":"e1012","DOI":"10.1200\/OP.20.00703","article-title":"Barriers to prescribing targeted therapies for patients with NSCLC with highly actionable gene variants in the Veterans Affairs National Precision Oncology Program","volume":"17","author":"Vashistha","journal-title":"JCO Oncol Pract"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.13976.1","article-title":"Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: a qualitative interview protocol","volume":"3","author":"Wright","journal-title":"Wellcome Open Res"},{"issue":"35","key":"R12","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1080\/14796694.2024.2390821","article-title":"Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review","volume":"20","author":"Ferreira-Gonzalez","journal-title":"Future Oncol"},{"issue":"12","key":"R13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/gim.2014.60","article-title":"The business of genomic testing: a survey of early adopters","volume":"16","author":"Crawford","journal-title":"Genet Med"},{"issue":"4","key":"R14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2217\/pme-2016-0104","article-title":"Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel\u2019s solutions","volume":"14","author":"Messner","journal-title":"Per Med"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atg.2016.05.004","article-title":"Barriers to clinical adoption of next generation sequencing: perspectives of a policy Delphi panel","volume":"10","author":"Messner","journal-title":"Appl Transl Genom"},{"issue":"4","key":"R16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040032","article-title":"The implementation process for pharmacogenomic testing for cancer-targeted therapies","volume":"8","author":"Wu","journal-title":"J Pers Med"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.6004\/jnccn.2015.0043","article-title":"Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in","volume":"13","author":"Trosman","journal-title":"J Natl Compr Canc Netw"},{"key":"R18","unstructured":"Veterans Affairs: National Oncology Program. URL: https:\/\/www.cancer.va.gov\/ [Accessed 25-03-2026]"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/qshc.2004.011155","article-title":"Making psychological theory useful for implementing evidence based practice: a consensus approach","volume":"14","author":"Michie","journal-title":"Qual Saf Health Care"},{"issue":"4","key":"R20","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/j.1475-6773.2006.00684.x","article-title":"Qualitative data analysis for health services research: developing taxonomy, themes, and theory","volume":"42","author":"Bradley","journal-title":"Health Serv Res"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0605-9","article-title":"A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems","volume":"12","author":"Atkins","journal-title":"Implement Sci"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-42","article-title":"The behaviour change wheel: a new method for characterising and designing behaviour change interventions","volume":"6","author":"Michie","journal-title":"Implement Sci"},{"issue":"9","key":"R23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis","volume":"15","author":"Hsieh","journal-title":"Qual Health Res"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1525822X19838237","article-title":"A team-based approach to open coding: considerations for creating intercoder consensus","volume":"31","author":"Cascio","journal-title":"Field methods"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pme-2021-0048","article-title":"Clinician perspectives on communication and implementation challenges in precision oncology","volume":"18","author":"Hamilton","journal-title":"Per Med"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.3389\/frhs.2023.1015621","article-title":"RAPID framework for improved access to precision oncology for lethal disease: results from a modified multi-round Delphi study","volume":"3","author":"Bright","journal-title":"Front Health Serv"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00708","article-title":"Scoping review of barriers and facilitators to recruitment of black people with Cancer in Biospecimen-Based research","volume":"8","author":"Morris","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"R28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.2013.52.4298","article-title":"Physicians\u2019 attitudes about multiplex tumor genomic testing","volume":"32","author":"Gray","journal-title":"J Clin Oncol"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18865\/ed.32.1.39","article-title":"Navigating access to cancer care: identifying barriers to precision cancer medicine","volume":"32","author":"Cooper","journal-title":"Ethn Dis"},{"issue":"2","key":"R30","doi-asserted-by":"publisher","DOI":"10.2196\/35033","article-title":"Patient and provider perspectives on enrollment in precision oncology research: qualitative ethical analysis","volume":"8","author":"Spector-Bagdady","journal-title":"JMIR Cancer"},{"key":"R31","unstructured":"Serving her country: exploring the characteristics of women veterans. US Department of Veterans Affairs. URL: https:\/\/www.data.va.gov\/stories\/s\/wci3-yrsv [Accessed 25-03-2026]"},{"issue":"2","key":"R32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","journal-title":"Cancer"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.11606\/s1518-8787.2022056004164","article-title":"Social desirability bias in qualitative health research","volume":"56","author":"Bispo J\u00fanior","journal-title":"Rev Saude Publica"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Institute of Medicine (US) Committee on Cancer Research Among Minorities and the Medically Underserved. Haynes MA Smedley BD , editors. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. National Academies Press; 1999. [doi: 10.17226\/6377] [Medline: 20845564]","DOI":"10.17226\/6377"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e84858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:18:57Z","timestamp":1782843537000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e84858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":34,"URL":"https:\/\/doi.org\/10.2196\/84858","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"v12i19e84858"}}